enGene (ENGN) Competitors $3.68 +0.07 (+1.94%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$3.70 +0.01 (+0.41%) As of 08/15/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENGN vs. NRIX, IMTX, MNMD, BGM, TNGX, QURE, DNA, STOK, TLRY, and PHATShould you be buying enGene stock or one of its competitors? The main competitors of enGene include Nurix Therapeutics (NRIX), Immatics (IMTX), Mind Medicine (MindMed) (MNMD), BGM Group (BGM), Tango Therapeutics (TNGX), uniQure (QURE), Ginkgo Bioworks (DNA), Stoke Therapeutics (STOK), Tilray Brands (TLRY), and Phathom Pharmaceuticals (PHAT). These companies are all part of the "pharmaceutical products" industry. enGene vs. Its Competitors Nurix Therapeutics Immatics Mind Medicine (MindMed) BGM Group Tango Therapeutics uniQure Ginkgo Bioworks Stoke Therapeutics Tilray Brands Phathom Pharmaceuticals Nurix Therapeutics (NASDAQ:NRIX) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, media sentiment, valuation, earnings, analyst recommendations, risk and profitability. Do insiders & institutionals have more ownership in NRIX or ENGN? 64.2% of enGene shares are held by institutional investors. 7.4% of Nurix Therapeutics shares are held by insiders. Comparatively, 10.4% of enGene shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media refer more to NRIX or ENGN? In the previous week, enGene had 10 more articles in the media than Nurix Therapeutics. MarketBeat recorded 12 mentions for enGene and 2 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 0.93 beat enGene's score of 0.25 indicating that Nurix Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Which has preferable valuation & earnings, NRIX or ENGN? enGene has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNurix Therapeutics$54.55M14.83-$193.57M-$2.61-4.05enGeneN/AN/A-$55.14M-$1.65-2.23 Is NRIX or ENGN more profitable? enGene has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -234.57%. enGene's return on equity of -32.60% beat Nurix Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nurix Therapeutics-234.57% -45.26% -34.71% enGene N/A -32.60%-28.26% Do analysts recommend NRIX or ENGN? Nurix Therapeutics presently has a consensus target price of $28.87, suggesting a potential upside of 172.84%. enGene has a consensus target price of $23.29, suggesting a potential upside of 532.76%. Given enGene's stronger consensus rating and higher probable upside, analysts clearly believe enGene is more favorable than Nurix Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nurix Therapeutics 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.81enGene 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more volatility & risk, NRIX or ENGN? Nurix Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, enGene has a beta of -0.41, suggesting that its share price is 141% less volatile than the S&P 500. SummaryenGene beats Nurix Therapeutics on 12 of the 16 factors compared between the two stocks. Get enGene News Delivered to You Automatically Sign up to receive the latest news and ratings for ENGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ENGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENGN vs. The Competition Export to ExcelMetricenGeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$184.49M$3.09B$5.66B$9.82BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-2.2320.3830.5825.12Price / SalesN/A356.76462.42114.82Price / CashN/A42.3037.4059.05Price / Book0.698.659.096.18Net Income-$55.14M-$54.65M$3.25B$264.89M7 Day PerformanceN/A6.58%7.32%4.18%1 Month Performance1.66%7.54%5.41%1.99%1 Year Performance-39.57%13.73%30.66%24.22% enGene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENGNenGene3.3331 of 5 stars$3.68+1.9%$23.29+532.8%-37.6%$184.49MN/A-2.2331Short Interest ↓NRIXNurix Therapeutics2.592 of 5 stars$9.65-1.9%$28.87+199.1%-52.3%$752.26M$54.55M-3.70300IMTXImmatics2.2707 of 5 stars$6.34+2.6%$14.67+131.3%-45.0%$751.18M$168.65M-37.29260News CoverageEarnings ReportMNMDMind Medicine (MindMed)2.4473 of 5 stars$10.00+1.5%$24.71+147.1%+49.7%$749.47MN/A-6.5440BGMBGM GroupN/A$7.61-1.2%N/AN/A$748.61M$25.10M0.00298TNGXTango Therapeutics1.9418 of 5 stars$6.41-3.0%$10.33+61.2%-28.0%$735.43M$42.07M-4.8290News CoveragePositive NewsAnalyst RevisionQUREuniQure2.826 of 5 stars$14.09+6.1%$36.55+159.4%+140.4%$728.63M$27.12M-3.59500Analyst UpgradeDNAGinkgo Bioworks0.9774 of 5 stars$11.87-3.5%$8.50-28.4%N/A$719.36M$227.04M-2.02640STOKStoke Therapeutics4.142 of 5 stars$13.16+0.5%$25.80+96.0%+27.8%$715.22M$36.56M16.66100Trending NewsEarnings ReportAnalyst ForecastInsider TradeAnalyst RevisionTLRYTilray Brands2.4037 of 5 stars$0.92+41.7%$1.92+108.6%-47.2%$713.91M$821.31M-0.402,842Gap UpHigh Trading VolumePHATPhathom Pharmaceuticals3.1264 of 5 stars$10.28+5.5%$17.50+70.2%-21.9%$690.99M$55.25M-2.17110News Coverage Related Companies and Tools Related Companies NRIX Competitors IMTX Competitors MNMD Competitors BGM Competitors TNGX Competitors QURE Competitors DNA Competitors STOK Competitors TLRY Competitors PHAT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENGN) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump's New Plan to “Make China Pay”Trump's AI Masterplan Could Crush China The White House just unleashed would could be the most aggressive e...Stansberry Research | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enGene Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share enGene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.